Disease · MONDO_0005556
Comparisons in its trials71
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 71
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Belimumab 10 mg/kg vs Placebo: Double-blind Period: Number of Participants With Time to Death or Renal Related Event | 35 of 223 | 63 of 223 | 446 | NCT01639339 | Trial comparisons |
| Abatacept IV vs Placebo IV: Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period | 7 of 202 | 9 of 203 | 405 | NCT01714817 | Trial comparisons |
| Abatacept IV vs Placebo IV: deaths from any cause | 7 of 202 | 6 of 203 | 405 | NCT01714817 | Trial comparisons |
| Abatacept IV vs Placebo IV: serious adverse events | 62 of 202 | 58 of 203 | 405 | NCT01714817 | Trial comparisons |
| Voclosporin vs Placebo Oral Capsule: deaths from any cause | 1 of 178 | 5 of 178 | 356 | NCT03021499 | Trial comparisons |
| Voclosporin vs Placebo Oral Capsule: serious adverse events | 37 of 178 | 38 of 178 | 356 | NCT03021499 | Trial comparisons |
| Secukinumab 300 mg vs Placebo: deaths from any cause | 1 of 137 | 1 of 138 | 275 | NCT04181762 | Trial comparisons |
| Secukinumab 300 mg vs Placebo: serious adverse events | 30 of 137 | 39 of 138 | 275 | NCT04181762 | Trial comparisons |
| Obinutuzumab vs Placebo: Number of Participants With Adverse Events (AEs) | 126 of 136 | 117 of 132 | 268 | NCT04221477 | Trial comparisons |
| Obinutuzumab vs Placebo: deaths from any cause | 5 of 136 | 4 of 132 | 268 | NCT04221477 | Trial comparisons |
| Obinutuzumab vs Placebo: serious adverse events | 44 of 136 | 24 of 132 | 268 | NCT04221477 | Trial comparisons |
| Mycophenolate Mofetil (MMF) vs Azathioprine (AZA): Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With End-stage Renal Disease (ESRD) | 0 of 116 | 3 of 111 | 227 | NCT00377637 | Trial comparisons |
| Mycophenolate Mofetil vs Azathioprine: Maintenance Phase: Participants With Major Extra-renal Flare | 7 of 116 | 6 of 111 | 227 | NCT00377637 | Trial comparisons |
| Mycophenolate Mofetil vs Azathioprine: Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With Sustained Doubling of Serum Creatinine | 1 of 116 | 5 of 111 | 227 | NCT00377637 | Trial comparisons |
| Voclosporin vs Placebo Oral Capsule: deaths from any cause | 0 of 116 | 3 of 100 | 216 | NCT03597464 | Trial comparisons |
| Voclosporin vs Placebo Oral Capsule: serious adverse events | 21 of 116 | 23 of 100 | 216 | NCT03597464 | Trial comparisons |
| Abatacept vs Placebo: serious adverse events | 28 of 69 | 26 of 68 | 137 | NCT00774852 | Trial comparisons |
| Abatacept vs Placebo: Number of Participants Fulfilling the Proteinuria and Prednisone Criteria of a Complete Response | 22 of 66 | 21 of 68 | 134 | NCT00774852 | Trial comparisons |
| Abatacept vs Placebo: Number of Participants Fulfilling the Proteinuria and Prednisone Criteria of a Partial Response | 39 of 66 | 42 of 68 | 134 | NCT00774852 | Trial comparisons |
| Abatacept vs Placebo: Number of Participants With Partial Response | 39 of 66 | 40 of 68 | 134 | NCT00774852 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005556/comparisons